Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;36(4):189-95.
doi: 10.1016/j.tips.2015.02.001. Epub 2015 Feb 27.

Novel therapeutic targets in rheumatoid arthritis

Marije I Koenders  1 , Wim B van den Berg  2
Affiliations
Review

Novel therapeutic targets in rheumatoid arthritis

Marije I Koenders et al. Trends Pharmacol Sci. 2015 Apr.

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease that leads to inflammation and destruction of synovial joints. Despite the broad spectrum of antirheumatic drugs, this heterogeneous disease is still not well controlled in up to 30% of patients. Here, we discuss two pathways that are regarded as interesting novel therapeutic targets in the field of rheumatology: the Janus kinase (JAK) pathway and the T helper-17 (Th17) pathway [including interleukin (IL)-17, IL-21, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF)]. We also review the therapy potential of biologicals and small-molecule inhibitors blocking these pathways. Advances in combination therapy in addition to progress in biomarker screening will help us to further achieve effective and personalized healthcare for patients with RA.

Keywords: IL-17; JAK; Th17; rheumatoid arthritis; therapeutic targets.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources